San Francisco startup Construction Therapeutics is usually working on an oral, after-day-to-day GLP-one drug referred to as GSBR-1290—the drug surpassed Wall Road’s expectations in June each time a mid-phase study showed typical weight loss of about six% and it designs to start Yet another mid-stage demo toward the top of this year—that found